Completed PHASE2 INTERVENTIONAL 2-arm NCT00265148

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Effects of Avandia on Cognition and Cerebral Glucose Utilisation in Subjects With Mild to Moderate Alzheimer's Disease (AD).

Sponsor: GlaxoSmithKline

Conditions Alzheimer's Disease

Interventions Placebo Rosiglitazone

Updated 7 times since 2017 Last updated: Oct 27, 2020 Started: May 18, 2004 Primary completion: Jul 10, 2008 Completion: Jul 10, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00265148, this PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Belmont, United States , Durham, United States , Litchfield Park, United States , Liverpool, United Kingdom , Los Angeles, United States , Manchester, United Kingdom , Montreal, Canada , Phoenix, United States , Scottsdale, United States and 4 more locations